Biologic Therapy in Rare Eosinophil-Associated Disorders

Read full text Summarise with VIRAT
Authors: Carla Mastrorilli, Fabio Cardinale
Cited by: 0
References: 27

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Our understanding of the contribution of eosinophils in the pathogenesis of various diseases has grown, particularly in disorders affecting the airways, gastrointestinal tract, and skin. This has led to the development of therapies that specifically target eosinophils or cytokines responsible for their production, activation, and survival – establishing a more focused and effective treatment approach. Recent biologic agents are designed to selectively inhibit eosinophils, cells that interact with or activate them, or components of the type 2 inflammatory cascade, using monoclonal antibodies. Currently, clinical guidelines generally reserve biologic therapies for patients who are refractory to or intolerant of corticosteroids or immunosuppressants. However, increasing evidence supporting the safety and efficacy of these agents has sparked a growing debate on whether earlier use of biologics could be beneficial. In the present article, we examine the benefits and limitations of currently approved biologics for the treatment of eosinophilic diseases involving the airways, gastrointestinal tract, and skin. Additionally, we discuss emerging biologic therapies, future research directions, and the rationale for considering early intervention with biologics to prevent irreversible tissue damage, disease progression, and organ dysfunction in selected cases.

Fields of Study & Subjects

Asthma and respiratory diseases Eosinophilic Disorders and Syndromes Eosinophilic Esophagitis

Publication details

Journal / source
Rivista di immunologia ed allergologia pediatrica.
Volume
39
Issue
4
Pages
69–72
Publication date
1 January 2026
Language
EN